TrialTargeted oncology2015

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Evelyn Despierre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.